Charles D. Blizzard
24Patents
8h-index
27Co-inventors
75Inventor score
Filing activity: Aug 19, 1996 → Jul 28, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6090925A | Macromolecular microparticles and methods of production and use | Emerging Cross-Sectional Technologies | 291 | Expired |
| US5981719A | Macromolecular microparticles and methods of production and use | Emerging Cross-Sectional Technologies | 258 | Expired |
| US6268053A | Macromolecular microparticles and methods of production and use | Emerging Cross-Sectional Technologies | 162 | Expired |
| US6458387B1 | Sustained release microspheres | Emerging Cross-Sectional Technologies | 156 | Expired |
| US8409606B2 | Drug delivery through hydrogel plugs | Human Necessities | 48 | Active |
| US8563027B2 | Drug delivery through hydrogel plugs | Human Necessities | 35 | Active |
| US10420724B2 | Shape changing drug delivery devices and methods | Human Necessities | 26 | Active |
| US10786462B2 | Shape changing drug delivery devices and methods | Human Necessities | 23 | Active |
| US8614255B2 | Pulmonary pharmaceutical formulations | Human Necessities | 7 | Active |
| US11534396B2 | Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor | Human Necessities | 4 | Active |
| US11291627B1 | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine | Human Necessities | 3 | Active |
| US11331267B2 | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine | Human Necessities | 3 | Active |
| US11439592B2 | Ocular implant containing a tyrosine kinase inhibitor | Human Necessities | 2 | Active |
| US11369591B2 | Drug delivery from hydrogels | Human Necessities | 2 | Active |
| US11622935B2 | Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles | Chemistry; Metallurgy | 1 | Active |
| US11779536B2 | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine | Human Necessities | 1 | Active |
| US12161753B2 | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent | Human Necessities | 0 | Active |
| US11938223B2 | Shape changing drug delivery devices and methods | Human Necessities | 0 | Active |
| US12329853B2 | Compositions and methods for treating ocular diseases | Chemistry; Metallurgy | 0 | Active |
| US11413250B2 | Shape changing drug delivery devices and methods | Human Necessities | 0 | Active |
| US12109302B2 | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine | Human Necessities | 0 | Active |
| US12357565B2 | Ocular implant containing a tyrosine kinase inhibitor | Human Necessities | 0 | Active |
| US5849884A | Macromolecular microparticles and methods of production and use | General | 0 | Revoked |
| US12171869B2 | Intracameral drug delivery depots | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.